164 related articles for article (PubMed ID: 38323272)
1. Urinary volatile organic compounds in prostate cancer biopsy pathologic risk stratification using logistic regression and multivariate analysis models.
Badmos S; Noriega-Landa E; Holbrook KL; Quaye GE; Su X; Gao Q; Chacon AA; Adams E; Polascik TJ; Feldman AS; Annabi MM; Lee WY
Am J Cancer Res; 2024; 14(1):192-209. PubMed ID: 38323272
[TBL] [Abstract][Full Text] [Related]
2. Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer.
Gao Q; Su X; Annabi MH; Schreiter BR; Prince T; Ackerman A; Morgas S; Mata V; Williams H; Lee WY
Clin Genitourin Cancer; 2019 Jun; 17(3):183-190. PubMed ID: 30853355
[TBL] [Abstract][Full Text] [Related]
3. Urinary fatty acid biomarkers for prostate cancer detection.
Noriega Landa E; Quaye GE; Su X; Badmos S; Holbrook KL; Polascik TJ; Adams ES; Deivasigamani S; Gao Q; Annabi MH; Habib A; Lee WY
PLoS One; 2024; 19(2):e0297615. PubMed ID: 38335180
[TBL] [Abstract][Full Text] [Related]
4. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
6. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
8. Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection.
Barisiene M; Bakavicius A; Stanciute D; Jurkeviciene J; Zelvys A; Ulys A; Vitkus D; Jankevicius F
Biomed Res Int; 2020; 2020():9872146. PubMed ID: 32775459
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
10. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
[TBL] [Abstract][Full Text] [Related]
11. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
12. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ; van der Leest MMG; Israël B; Hannink G; YantiSetiasti A; Cornel EB; Hulsbergen-van de Kaa CA; Klaver OS; Sedelaar JPM; Van Criekinge W; de Jong H; Mulders PFA; Crawford ED; Veltman J; Schalken JA; Barentsz JO; van Oort IM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1110-1119. PubMed ID: 33941866
[TBL] [Abstract][Full Text] [Related]
14. Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers.
Tyagi H; Daulton E; Bannaga AS; Arasaradnam RP; Covington JA
Biosensors (Basel); 2021 Nov; 11(11):. PubMed ID: 34821653
[TBL] [Abstract][Full Text] [Related]
15. Analysis of urinary VOCs using mass spectrometric methods to diagnose cancer: A review.
da Costa BRB; De Martinis BS
Clin Mass Spectrom; 2020 Nov; 18():27-37. PubMed ID: 34820523
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
17. Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
Alijaj N; Pavlovic B; Martel P; Rakauskas A; Cesson V; Saba K; Hermanns T; Oechslin P; Veit M; Provenzano M; Rüschoff JH; Brada MD; Rupp NJ; Poyet C; Derré L; Valerio M; Banzola I; Eberli D
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267445
[TBL] [Abstract][Full Text] [Related]
18. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
19. Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men.
Isotani S; Ka-Fung Chiu P; Ashizawa T; Fung YH; Ieda T; China T; Kawano H; Shimizu F; Nagata M; Nakagawa Y; Muto S; Wong KL; Ng CF; Horie S
Prostate Int; 2023 Sep; 11(3):180-185. PubMed ID: 37745906
[TBL] [Abstract][Full Text] [Related]
20. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
